A review of the use of latanoprost for glaucoma since its launch

Bibliography

• Alward WL. Medical management of glaucoma. N Engl J Med 1998;29339(18):1298-307
   PubMed Web of Science ®Google Scholar
• Sommer A. Intraocular pressure and glaucoma. Am J Ophthalmol 1989;15:107(2):186-8
   Google Scholar
• Chung HS, Harris A, Evans DW, Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Surv Ophthalmol 1999;43(Suppl 1):S43-50
   PubMed Web of Science ®Google Scholar
• Perry CM, Mc Gavin JK, Culy CR, Ibbotson T. Latanoprost. An update of its use in glaucoma and ocular hypertension. Drugs Aging 2003;20:597-630
   PubMed Web of Science ®Google Scholar
• Aquino MV, Lat-Luna M. The effect of latanoprost vs. timolol on intraocular pressure in patients with glaucoma and ocular hypertension. Asian J Ophthalmol 1999;1:3-7
   Google Scholar
• Leonard R. Statistics on Vision Impairment: A Resource Manual. In: Leonard RArlene R. editor; 5th edition. Gordon Research Institute of Lighthouse International; New York, USA: 2002
   Google Scholar
• European Glaucoma Society. Terminology and Guidelines for Glaucoma. 3rd edition. Editrice DOGMA S.r.l; Savona, Italy: 2008
   Google Scholar
• Rossetti L, Goni F, Denis P, Focusing on glaucoma progression and the clinical importance of progression rate measurement: a review. Eye (Lond) 2010;24(Suppl 1):S1-7
   PubMedGoogle Scholar
• Hoyng PFJ, Van Beek LM. Pharmacological therapy for glaucoma. A review. Drugs 2000;59:411-34
   PubMed Web of Science ®Google Scholar
• Alm A, Widengard I, Kjellgren D, Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995;79:12-16
   PubMed Web of Science ®Google Scholar
• Bucci MG; The Italian Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. J Glaucoma 1999;8:24-30
   PubMed Web of Science ®Google Scholar
• Weinreb RN. Compliance with medical treatment of glaucoma. J Glaucoma 1992;1:134-6
   Google Scholar
• Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995;26:233-6
   PubMedGoogle Scholar
• Pfizer, Inc.: Xalatan® (Latanoprost) Package Insert. Pfizer, Inc; New York, NY, USA: 2003
   Google Scholar
• Lim KS, Nau CB, O'Byrne MM, Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology 2008;115(5):790-5
   PubMed Web of Science ®Google Scholar
• Nilsson SFE, Samuelsson M, Bill A, Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2, -l-isopropylesterin the cynomolgus monkey. Exp Eye Res 1989;48:707-16
   PubMed Web of Science ®Google Scholar
• Gabelt BT, Kaufman PL. Prostaglandin F2a increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989;49:389-402
   PubMed Web of Science ®Google Scholar
• Toris CB, Yablonski ME, Wang Y-L, Prostaglandin A2increases uveoscleral outflow and trabecular outflow facility in the cat. Exp Eye Res 1995;61:649-57
   PubMed Web of Science ®Google Scholar
• Toris CB, Camras CB, Yablonski ME. EffectsofPhXA41, a new prostaglandin Fk analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-304
   PubMed Web of Science ®Google Scholar
• Toris CB, Camras CB, Yablonski ME, Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous harrier function. Surv Ophthalmol 1997;41:S69-75
   PubMed Web of Science ®Google Scholar
• Stjernschantz J, SeEn G, Ocklind A, Effects of latanoprost and related prostaglandin analogues. In: Alm A, Weinreb R, editors. Uveoscleral Outflow. Mosby-Wolfe; London: 1998. p. 57-72
   Google Scholar
• Poyer JF, Millar C, Kaufman PL, Prostaglandin F. Effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol 1995;36:2461-5
   Google Scholar
• Lindsey JD, Kashiwagi K, Kashiwagi F, Prostaglandin action on ciliary smooth muscle extracellularmatrix metabolism: implications for uveoscleral outflow. Surv Ophthalmol 1997;41:S53-9
   PubMed Web of Science ®Google Scholar
• Lindsey JD, Weinreb RN. Effects of prostaglandins on uveoscleral outflow. In: Ah A, Weinreb R, editors. Uveoscleral Outflow. Mosby-Wolfe; London: 1998. p. 41-55
   Google Scholar
• Brubaker RF. Targeting outflow facility in glaucoma management. Surv Ophthalmol 2003;48(Suppl 1):S17-20
   PubMed Web of Science ®Google Scholar
• Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 2002;47(Suppl 1):S6-S12
   PubMed Web of Science ®Google Scholar
• Sjoquist B, Ryding P, Stjernschantz J. The systemic pharmacokinetics of latanoprost in man after intravenous and topical administration. Paper Presented at ARVO; May 1994; Florida
   Google Scholar
• Bito LZ, Baroody RA. The ocular pharmacokinetics of eicosanoids and their derivatives. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha-1-methyl ester, and PGF2 alpha-1-isopropyl ester. Exp Eye Res 1987;44(2):217-26
   PubMed Web of Science ®Google Scholar
• Sjoquist B, Johasson A. The ocular pharmacokinetics of latanoprost, new antiglaucoma drug, studied by autoradiography. Invest Ophthalmol Vis Sci 1995;36(4):5823
   Web of Science ®Google Scholar
• Alvan G, Calissendorff B, Scideman P, Absorption of ocular timolol. Clin Pharmacokinet 1980;5:95
   PubMed Web of Science ®Google Scholar
• Basu S, Sjoquist B, Stjernschantz J, Corneal permeability and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukot Essent Fatty Acids 1994;50:161-8
   PubMed Web of Science ®Google Scholar
• Calissendorff B, Sjoquist B, Hogberg G, Grunge-Lowerud A. Bioavailability in the human eye of a fixed combination of latanoprost and timolol compared to monotherapy. J Ocul Pharmacol Ther 2002;18:127-31
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ, Diestelhorst M, Pfeiffer N, The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Surv Ophthalmol 2002;47(Suppl 1):S133-40
   PubMed Web of Science ®Google Scholar
• Patel SS, Spencer CM. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 1996;9(5):363-78
   PubMed Web of Science ®Google Scholar
• Diestelhorst M, Krieglstein GK, Lusky M, Nagasubramanian S. Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analog. Surv Ophthalmol 1997;41(Suppl 2):S77-81
   PubMedGoogle Scholar
• Fristrom B, Nilsson SE. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol 1993;111(5):662-5
   PubMedGoogle Scholar
• Xalatan: latanoprost ophthalmic solution [package insert]. New York: Pfizer and Upjohn Co.; 2009. Available from: http://www.pfizer.com/files/products/uspi_xalatan_multi.pdf
   Google Scholar
• Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995;102(12):1743-52
   PubMed Web of Science ®Google Scholar
• Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996;103(1):126-37
   PubMed Web of Science ®Google Scholar
• Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996;103(1):138-47
   PubMed Web of Science ®Google Scholar
• Aung T, Chew PT, Yip CC, A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 2001;131(5):636-42
   PubMed Web of Science ®Google Scholar
• Kimal Arici M, Topalkara A, Guler C. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Int Ophthalmol 1998;22(1):37-42
   PubMed Web of Science ®Google Scholar
• Rulo AH, Greve EL, Hoyng PF. Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure. Ophthalmology 1997;104(9):1503-7
   PubMed Web of Science ®Google Scholar
• DuBiner H, Cooke D, Dirks M, Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2001;45(Suppl 4):S353-60
   PubMed Web of Science ®Google Scholar
• Gandolfi S, Simmons ST, Sturm R, Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001;18(3):110-21
   PubMed Web of Science ®Google Scholar
• Konstas AG, Maltezos AC, Gandi S, Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol 1999;128(1):15-20
   PubMed Web of Science ®Google Scholar
• Larsson LI. Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension. Ophthalmology 2001;108(8):1439-44
   PubMed Web of Science ®Google Scholar
• Orzalesi N, Rossetti L, Invernizzi T, Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41(9):2566-73
   PubMed Web of Science ®Google Scholar
• Bron AM, Denis P, Nordmann JP, Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol. Acta Ophthalmol Scand 2001;79(3):289-93
   PubMedGoogle Scholar
• Netland PA, Landry T, Sullivan EK, Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132(4):472-84
   PubMed Web of Science ®Google Scholar
• Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma 2008;17(8):667-73
   PubMed Web of Science ®Google Scholar
• Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703
   PubMed Web of Science ®Google Scholar
• Noecker RS, Dirks MS, Choplin NT, A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55-63
   PubMed Web of Science ®Google Scholar
• Walters TR, DuBiner HB, Carpenter SP, 24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol 2004;49(Suppl 1):S26-35
   PubMedGoogle Scholar
• Cantor LB, Hoop JS, Morgan L, Intraocular pressure- lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol 2006;90:1370-3
   PubMed Web of Science ®Google Scholar
• Cantor LB, WuDunn D, Cortes A, Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004;49(Suppl 1):S12-18
   PubMedGoogle Scholar
• Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 2008;115(7):1117-22
   PubMed Web of Science ®Google Scholar
• Van der Valk R, Webers CA, Schouten JS, Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112(7):1177-85
   PubMed Web of Science ®Google Scholar
• Zhang WY, Po AL, Dua HS, Azuara-Blanco A. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol 2001;85:983-90
   PubMed Web of Science ®Google Scholar
• Einarson TR, Kulin NA, Tingey D, Iskedjian M. Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma. Clin Ther 2000;22:1502-15
   PubMed Web of Science ®Google Scholar
• Mishima HK, Masuda K, Kitazawa Y, A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 1996;114(8):929-32
   PubMedGoogle Scholar
• Suzuki M, Mishima HK, Masuda K, Efficacy and safety of latanoprost eye drops for glaucoma treatment: a 1-year study in Japan. Jpn J Ophthalmol 2000;44(1):33-8
   PubMed Web of Science ®Google Scholar
• Alm A, Widengard I. Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand 2000;78(1):71-6
   PubMedGoogle Scholar
• Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology 1998;105(1):82-7
   PubMed Web of Science ®Google Scholar
• Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 1996;103(11):1916-24
   PubMed Web of Science ®Google Scholar
• Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 2006;113(2):239-46
   PubMed Web of Science ®Google Scholar
• Racz P, Ruzsonyi MR, Nagy ZT, Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol 1996;114:268-73
   PubMed Web of Science ®Google Scholar
• Mishima HK, Kiuchi Y, Takamatsu M, Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveo- scleral outflow. Surv Ophthalmol 1997;41:S139-44
   PubMed Web of Science ®Google Scholar
• Larsson L, Mishima HK, Takamatsu M, The effect of latanoprost on circadian intraocular pressure. Surv Ophthalmol 2002;47:S90-6
   PubMed Web of Science ®Google Scholar
• Konstas AG, Katsimbris JM, Lallos N, Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 2005;112:262-6
   PubMed Web of Science ®Google Scholar
• Cheng JW, Wei RL. Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure. Clin Ther 2008;30(4):622-32
   PubMed Web of Science ®Google Scholar
• Susanna R Jr, Giampani J Jr, Borges AS, A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology 2001;108(2):259-63
   PubMed Web of Science ®Google Scholar
• Saito M, Takano R, Shirato S. Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma. Am J Ophthalmol 2001;132(4):485-9
   PubMed Web of Science ®Google Scholar
• Jampel HD, Bacharach J, Sheu WP, Latanoprost/Unoprostone Study Group. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am J Ophthalmol 2002;134(6):863-71
   PubMed Web of Science ®Google Scholar
• Kampik A, Arias-Puente A, O'Brart DP, Vuori ML; European Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J Glaucoma 2002;11(2):90-6
   PubMed Web of Science ®Google Scholar
• Stewart WC, Day DG, Stewart JA, The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;131(5):631-5
   PubMed Web of Science ®Google Scholar
• DuBiner HB, Mroz M, Shapiro AM, Dirks MS; Brimonidine vs. Latanoprost Study Group. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial. Clin Ther 2001;23(12):1969-83
   PubMed Web of Science ®Google Scholar
• Emmerich KH. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension. A 3-month randomised study. Graefes Arch Clin Exp Ophthalmol 2000;238(1):19-23
   PubMed Web of Science ®Google Scholar
• Garcia Sanchez J. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension-a three-month randomised study. Spanish Latanoprost Study Group. Eur J Ophthalmol 2000;10(3):198-204
   Web of Science ®Google Scholar
• Polo V, Larrosa JM, Gomez ML, Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma. Acta Ophthalmol Scand 2001;79(1):6-9
   PubMedGoogle Scholar
• Honrubia FM, Larsson LI, Spiegel D; European Latanoprost Study Group. A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma. Acta Ophthalmol Scand 2002;80(6):635-41
   PubMedGoogle Scholar
• Nordmann JP, Soderstrom M, Rouland JF, Malecaze F. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group. Br J Ophthalmol 2000;84(2):181-5
   PubMed Web of Science ®Google Scholar
• Pillunat LE, Larsson LI; European and Canadian Latanoprost Study Group. Intraocular pressure after replacement of current dual therapy with latanoprost monotherapy in patients with open angle glaucoma. Br J Ophthalmol 2003;87(12):1492-6
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-97
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• Choudhri S, Wand M, Shields MB. A comparison of dorzolamide–timolol combination versus the concomitant drugs. Am J Ophthalmol 2000;130:832-3
   PubMed Web of Science ®Google Scholar
• Hollo G, Chiselita D, Petkova N, The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Eur J Ophthalmol 2006;16:816-23
   PubMed Web of Science ®Google Scholar
• Hommer A, Kapik B, Shams N; The Unoprostone Adjunctive Therapy Study Group. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide. Br J Ophthalmol 2003;87:592-8
   PubMed Web of Science ®Google Scholar
• Strahlman ER, Vogel R, Tipping R, Clineschmidt CM. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group. Ophthalmology 1996;103:1283-93
   PubMed Web of Science ®Google Scholar
• Lee PY, Shao H, Camras CB, Podos SM. Additivity of prostaglandin F2 alpha-1-isopropyl ester to timolol in glaucoma patients. Ophthalmology 1991;98:1079-82
   PubMed Web of Science ®Google Scholar
• Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 1994;78:899-902
   PubMed Web of Science ®Google Scholar
• Miglior S, Grunden JW, Kwok K; Xalacom/Cosopt European Study Group. Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension. Eye (Lond) 2010;24(7):1234-42
   PubMed Web of Science ®Google Scholar
• Pfeiffer N; European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002;240(11):893-9
   PubMed Web of Science ®Google Scholar
• Shin DH, Feldman RM, Sheu WP; Fixed Combination Latanoprost/Timolol Study Group. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 2004;111(2):276-82
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ, Feldman R, Stiles M, Dubiner H; Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs. monotherapy: one-year randomized trial. Arch Ophthalmol 2002;120(7):915-22
   PubMed Web of Science ®Google Scholar
• Simmons ST, Earl ML; Alphagan/Xalatan Study Group. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering. Ophthalmology 2002;109(2):307-14
   PubMed Web of Science ®Google Scholar
• Diestelhorst M. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group. Graefes Arch Clin Exp Ophthalmol 2000;238(5):433-9
   PubMed Web of Science ®Google Scholar
• Petounis A, Mylopoulos N, Kandarakis A, Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece. J Glaucoma 2001;10(4):316-24
   PubMed Web of Science ®Google Scholar
• Widengard I, Maepea O, Alm A. Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability. Br J Ophthalmol 1998;82(4):404-6
   PubMed Web of Science ®Google Scholar
• Toris CB, Zhan GL, Zhao J, Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmol 2001;131(6):722-8
   PubMed Web of Science ®Google Scholar
• Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open- label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol 2004;122:957-65
   PubMed Web of Science ®Google Scholar
• O'Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 2002;133(6):836-7
   PubMed Web of Science ®Google Scholar
• Simmons ST, Samuelson TW. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group. Clin Ther 2000;22(4):388-99
   PubMed Web of Science ®Google Scholar
• Susanna R Jr, Nicolela MT, Oga E. Additive effect of latanoprost to the combination of timolol and dorzolamide. J Glaucoma 2000;9(2):183-6
   PubMed Web of Science ®Google Scholar
• Shin DH, McCracken MS, Bendel RE, The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy. Ophthalmology 1999;106(2):386-90
   PubMed Web of Science ®Google Scholar
• Patelska B, Greenfield DS, Liebmann JM, Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Am J Ophthalmol 1997;124(3):279-86
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Mori K, Ishibashi T, Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jpn J Ophthalmol 2006;50(2):153-7
   PubMed Web of Science ®Google Scholar
• Hedman K, Larsson LI. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol 2002;47(Suppl 1):S77-89
   PubMed Web of Science ®Google Scholar
• Choplin N, Bernstein P, Batoosingh AL, A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Surv Ophthalmol 2004;49(Suppl 1):S19-25
   PubMedGoogle Scholar
• Rossetti L, Gandolfi S, Traverso C, An evaluation of the rate of nonresponders to latanoprost therapy. J Glaucoma 2006;15(3):238-43
   PubMed Web of Science ®Google Scholar
• Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol 2000;10:95-104
   PubMed Web of Science ®Google Scholar
• Scherer WJ. A retrospective review of non-responders to latanoprost. J Ocul Pharmacol Ther 2002;18:287-91
   PubMed Web of Science ®Google Scholar
• Williams RD. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther 2002;19:275-81
   PubMed Web of Science ®Google Scholar
• Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology 2003;110:609-14
   PubMed Web of Science ®Google Scholar
• Woodward DF, Krauss AH, Chen J, The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol 2002;47:295
   Web of Science ®Google Scholar
• Konstas AG, Hollo G, Irkec M, Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study. Br J Ophthalmol 2007;91(6):757-60
   PubMed Web of Science ®Google Scholar
• Camras CB, Hedman K. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma 2003;12:466-9
   PubMed Web of Science ®Google Scholar
• Gaton DD, Sagara T, Lindsey JD, Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch Ophthalmol 2001;119:1165-70
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Kashiwagi K, Kashiwagi F, Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 1997;38:2772-80
   PubMed Web of Science ®Google Scholar
• Weinreb R, Toris C, Gabelt B, Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 2002;47:S53-64
   PubMed Web of Science ®Google Scholar
• Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 1998;67:179-91
   PubMed Web of Science ®Google Scholar
• Sagara T, Gaton DD, Lindsey JD, Topical prostaglandin F2 treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 1999;117:794-801
   PubMed Web of Science ®Google Scholar
• Camras CB, Schumer RA, Marsk A, Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch Ophthalmol 1992;110:1733-8
   PubMedGoogle Scholar
• Nagasubramanian S, Sheth GP, Hitchings RA, Intraocular pressurereducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology 1993;100:1305-11
   PubMed Web of Science ®Google Scholar
• Camras CB, Siebold EC, Lustgarten JS, Maintained reduction of intraocular pressure by prostaglandin F2-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology 1989;96:1329-37
   PubMed Web of Science ®Google Scholar
• Aung T, Wong HT, Yip CC, Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study. Ophthalmology 2000;107(6):1178-83
   PubMed Web of Science ®Google Scholar
• Chew PT, Exact Study Group. The Efficacy of Xalatan in Angle Closure Glaucoma Therapy (EXACT) Study. Poster presented at the Association for Research in Vision and Ophthalmology (ARVO). Annual Meeting 2001 April 29 - May 4
   Google Scholar
• Hung PT, Hsieh JW, Chen YF, Wei T. Efficacy of latanoprost as an adjunct to medical therapy for residual angle-closure glaucoma after iridectomy. J Ocul Pharmacol Ther 2000;16(1):43-7
   PubMed Web of Science ®Google Scholar
• McKibbin M, Menage MJ. The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma. Eye 1999;13:31-4
   PubMed Web of Science ®Google Scholar
• Drance SM, Crichton A, Mills RP. Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal tension glaucoma. Am J Ophthalmol 1998;125(6):585-92
   PubMedGoogle Scholar
• Rulo AH, Greve EL, Geijssen HC, Hoyng PF. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology 1996;103(8):1276-82
   PubMed Web of Science ®Google Scholar
• Greve EL, Rulo AH, Drance SM, Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment. Surv Ophthalmol 1997;41(Suppl 2):S89-92
   PubMedGoogle Scholar
• Konstas AG, Kozobolis VP, Katsimpris IE, Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology 2007;114(4):653-7
   PubMed Web of Science ®Google Scholar
• Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology 1999;106(3):550-5
   PubMed Web of Science ®Google Scholar
• Vetrugno M, Maino A, Quaranta GM, Cardia L. A randomized, comparative open-label study on the efficacy of latanoprost and timolol in steroid induced ocular hypertension after photorefractive keratectomy. Eur J Ophthalmol 2000;10(3):205-11
   PubMed Web of Science ®Google Scholar
• Scherer WJ, Hauber FA. Effect of latanoprost on intraocular pressure in steroid-induced glaucoma. J Glaucoma 2000;9(2):179-82
   PubMed Web of Science ®Google Scholar
• Altuna JC, Greenfield DS, Wand M, Latanoprost in glaucoma associated with Sturge-Weber syndrome: benefits and side-effects. J Glaucoma 1999;8(3):199-203
   PubMed Web of Science ®Google Scholar
• Yang CB, Freedman SF, Myers JS, Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome. Am J Ophthalmol 1998;126(4):600-2
   PubMed Web of Science ®Google Scholar
• Konstas AG, Lake S, Economou AI, 24-hour control with a latanoprost-timolol fixed combination vs. timolol alone. Arch Ophthalmol 2006;124:1553-7
   PubMed Web of Science ®Google Scholar
• Law SK, Song BJ, Fang E, Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization. Ophthalmology 2005;112:2123-30
   PubMed Web of Science ®Google Scholar
• Sharif NA, Kelly CR, Crider JY, Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding af-finities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 2003;19:501-15
   PubMed Web of Science ®Google Scholar
• Susanna R Jr, Medeiros FA. The pros and cons of different prostanoids in the medical management of glaucoma. Curr Opin Ophthalmol 2001;12(2):149-56
   PubMed Web of Science ®Google Scholar
• Hollo G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf 2007;6:45-52
   PubMed Web of Science ®Google Scholar
• Feldman RM. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther 2003;19:23-35
   PubMed Web of Science ®Google Scholar
• Stewart WC, Kolkler AE, Stewart JA, Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol 2003;135:314-20
   PubMed Web of Science ®Google Scholar
• Stjernschantz JW. From PGF (2 alpha)-isopropylester to latanoprost: a review of the development of xalatan: the Proctor lecture. Invest Ophthalmol Vis Sci 2001;42:1134-45
   PubMed Web of Science ®Google Scholar
• Honrubia F, Garcia-Sanchez J, Polo V, Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogs in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol 2009;93(3):316-21
   PubMed Web of Science ®Google Scholar
• Arcieri ES, Santana A, Rocha FN, Blood–aqueous barrier changes after the use of prostaglandin analogs in patients with pseudophakia and aphakia. Arch Ophthalmol 2005;123:186-92
   PubMed Web of Science ®Google Scholar
• Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41(Suppl 2):S129-38
   PubMedGoogle Scholar
• Grierson I, Lee WR, Albert DM. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change. Arch Ophthalmol 1999;117(3):394-6
   PubMedGoogle Scholar
• Smith-Thomas L, Moustafa M, Spada CS, Latanoprost-induced pigmentation in human iridial melanocytes is fibroblast dependent. Exp Eye Res 2004;78(5):973-85
   PubMed Web of Science ®Google Scholar
• Demitsu T, Manabe M, Harima N, Hypertrichosis induced by latanoprost. J Am Acad Dermatol 2001;44(4):721-3
   PubMed Web of Science ®Google Scholar
• Chiba T, Kashiwagi K, Kogure S, Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients. J Glaucoma 2001;10(5):406-10
   PubMed Web of Science ®Google Scholar
• Latanoprost-Induced Iris Pigmentation Study Group. Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes. Jpn J Ophthalmol 2006;50(2):96-9
   PubMed Web of Science ®Google Scholar
• Hara T. Increased iris pigmentation after use of latanoprost in Japanese brown eyes. Nippon Ganka Gakkai Zasshi (J Jpn Oph- thalmol Soc) 2001;105:314-21
   PubMedGoogle Scholar
• Chiba T, Kashiwagi K, Ishijima K, A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost. Jpn J Ophthalmol 2004;48:141-7
   PubMed Web of Science ®Google Scholar
• Tsai JC, Sivak-Callcott JA, Haik BG, Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report. J Glaucoma 2001;10:411-13
   PubMed Web of Science ®Google Scholar
• Albert DM, Gangnon RE, Zimbric ML, A study of iridec- tomy histopathologic features of latanoprost- and non-latanoprost- treated patients. Arch Ophthalmol 2004;122:1680-5
   PubMedGoogle Scholar
• Grierson I, Jonsson M, Cracknell K. Latanoprost and pigmentation. Jpn J Ophthalmol 2004;48:602-12
   PubMed Web of Science ®Google Scholar
• Arranz-Marquez E, Teus MA, Saornil MA, Analysis of irises with a latanoprost-induced change in iris color. Am J Ophthalmol 2004;138:625-30
   PubMed Web of Science ®Google Scholar
• Krohn J, Hove VK. Iris cyst associated with topical administration of latanoprost. Am J Ophthalmol 1999;127:91-3
   PubMed Web of Science ®Google Scholar
• Browning DJ, Perkins SL, Lark KK. Iris cyst secondary to latanoprost mimicking iris melanoma. Am J Ophthalmol 2003;135:419-21
   PubMed Web of Science ®Google Scholar
• Lai IC, Kuo MT, Teng LMC. Iris pigment epithelial cyst induced by topical administration of latanoprost. Br J Ophthalmol 2003;87:366
   PubMed Web of Science ®Google Scholar
• Gentile RC, Leibmann JM, Tello C, Ciliary body enlargement and cyst formation in uveitis. Br J Ophthalmol 1996;80:895-9
   PubMed Web of Science ®Google Scholar
• Gupta V, Rao A, Sinha A, Kumar N. Post-traumatic inclusion cysts of the iris: a longterm perspective series. Acta Ophthalmol Scand 2007;85:893-6
   PubMedGoogle Scholar
• Sodhi PK. Iris cyst secondary to latanoprost mimicking iris melanoma. Am J Ophthalmol 2003;136:780
   PubMed Web of Science ®Google Scholar
• Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol 2002;47(Suppl 1):S185-202
   PubMed Web of Science ®Google Scholar
• Burnett JW, Harvey VM. Circumscribed palmar or plantar hypokeratosis: report of two additional cases. J Am Acad Dermatol 2004;51:843-4
   PubMed Web of Science ®Google Scholar
• Johnstone MA. Hypertrichosis and increased pigmentation of eye- lashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 2001;132(4):472-84
   PubMedGoogle Scholar
• Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol 1997;115(9):1206-8
   PubMed Web of Science ®Google Scholar
• Shaikh MY, Bodla AA. Hypertrichosis of the eyelashes from pros- taglandin analog use: a blessing or a bother to the patient? J Ocul Pharmacol Ther 2006;22(1):76-7
   PubMed Web of Science ®Google Scholar
• Demitsu T, Manabe M, Harima N, Hypertrichosis induced by latanoprost. J Am Acad Dermatol 2001;44(4):721-3
   PubMed Web of Science ®Google Scholar
• Inouye K, Wakakura M, Inoue J, Adverse reaction after use of latanoprost in Japanese glaucoma patients. Nippon Ganka Gakkai Zasshi 2006;110:581-7
   PubMedGoogle Scholar
• Elgin U, Batman A, Becker N, Iihan B. The comparison of eyelash lengthening effect of latanoprost therapy in adults and children. Eur J Ophthalmol 2006;16:247-50
   PubMed Web of Science ®Google Scholar
• Reynolds A, Murray PI, Colloby PS. Darkening of eyelashes in a patient treated with latanoprost. Eye 1998;12:741-3
   PubMed Web of Science ®Google Scholar
• Johnstone MA. Hypertrichosis and increased pigmentation of eye- lashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997;124:544-7
   PubMed Web of Science ®Google Scholar
• Strober BE, Potash S, Grossman ME. Eyelash hypertrichosis in a patient treated with topical latanoprost. Cutis 2001;67:109-10
   PubMed Web of Science ®Google Scholar
• Brandt JD, VanDenburgh AM, Chen K, Bimatoprost Study Group. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology 2001;108:1023-31
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration, Division of Anti-infective and Ophthalmology Products Advisory Committee. Briefing information: bimatoprost ophthalmic solution for the treatment of hypotrichosis of the eyelashes. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4397b1-03-FDA.pdf [Accessed 30 September 2011]
   Google Scholar
• O'Toole L, Cahill M, O'Brien C. Eyelid hypertrichosis associated with latanoprost is reversible. Eur J Ophthalmol 2001;11:377-9. 70
   PubMed Web of Science ®Google Scholar
• Chen CS, Wells J, Craig JE. Topical prostaglandin F2 analog induced poliosis. Am J Ophthalmol 2004;137:965-6
   PubMed Web of Science ®Google Scholar
• Wand M, Ritch R, Isbey EK Jr, Zimmerman TJ. Latanoprost and periocular skin color changes. Arch Ophthalmol 2001;119:614-15
   PubMed Web of Science ®Google Scholar
• Kook MS, Lee K. Increased eyelid pigmentation associated with use of latanoprost. Am J Ophthalmol 2000;129:804-6
   PubMed Web of Science ®Google Scholar
• Herndon LW, Williams RD, Wand M, Asrani S. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans. Am J Ophthalmol 2003;135:713-15
   PubMed Web of Science ®Google Scholar
• Abdel-Malek ZA, Swope VB, Amornsiripanitch N, Nordlund JJ. In vitro modulation of proliferation and melanization of S91 melanoma cells by prostaglandins. Cancer Res 1987;47:3141-6
   PubMed Web of Science ®Google Scholar
• Woodward DR, Regan JW, Lake S, Ocklind A. The molecular biology and ocular distribution of prostanoid receptors. Surv Ophthalmol 1997;41:S15-21
   PubMed Web of Science ®Google Scholar
• Imesch PD, Wallow IHL, Albert DM. The color of the human eye. A review of morphologic correlates and of some conditions that affect iridial pigmentation. Surv Ophthalmol 1997;41:S117-23
   PubMed Web of Science ®Google Scholar
• Jimbow K. Formation, chemical compositions and functions of melanin pigments in mammals. In: Matoltsy AG, editor. Biology of the Integument. Springer Verlag; New York; 1986. p. 278
   Google Scholar
• Centofanti M, Oddone F, Chimenti S, Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy. Am J Ophthalmol 2006;142(6):1059-60
   PubMed Web of Science ®Google Scholar
• Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relation? Curr Opin Ophthalmol 2000;11(2):94-100
   PubMedGoogle Scholar
• Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol 1997;41(Suppl 2):S105-10
   PubMedGoogle Scholar
• Miyake K, Ota I, Maekubo K, Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early post-operative pseudophakias. Arch Ophthalmol 1999;117:34-40
   PubMed Web of Science ®Google Scholar
• Smith SL, Pruitt CA, Sine CS, Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand 1999;77(6):668-72
   PubMedGoogle Scholar
• Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998;105(2):263-8
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Khouri AS, Zimmerman TJ, Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998;126(1):37-41
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45
   PubMed Web of Science ®Google Scholar
• Ayyala RS, Cruz DA, Margo CE, Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol 1998;126:602-4
   PubMed Web of Science ®Google Scholar
• Camras CB, Bhuyan KC, Podos M, Multiple dosing of prostaglandin F2a or epinephrine on cynomolgus monkey eyes: II. Slit-lamp biomicroscopy, aqueous humor analysis, and fluorescein angiography. Invest Ophthalmol Vis Sci 1987;28:921-6
   PubMed Web of Science ®Google Scholar
• Yousufazi SY, Abdel-Latif AA. Prostaglandin F2a and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species. Exp Eye Res 1996;63:305-10
   PubMed Web of Science ®Google Scholar
• Sacca S, Pascotto A, Siniscalchi C, Rolando M. Ocular complications of latanoprost in uveitic glaucoma: three case reports. J Ocul Pharmacol Ther 2001;17(2):107-13
   PubMed Web of Science ®Google Scholar
• Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008;53(Suppl 1):S93-105
   PubMed Web of Science ®Google Scholar
• Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol 1999;127(5):602-4
   PubMed Web of Science ®Google Scholar
• Ekatomatis P. Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma. Br J Ophthalmol 2001;85(8):1008-9
   PubMed Web of Science ®Google Scholar
• Kroll DM, Schuman JS. Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am J Ophthalmol 2002;133:401-3
   PubMed Web of Science ®Google Scholar
• Deai T, Fukuda M, Hibino T, Herpes simplex virus genome quantification in two patients who developed herpetic epithelial keratitis during treatment with antiglaucoma medications. Cornea 2004;23(2):125-8
   PubMed Web of Science ®Google Scholar
• Kaufman HE, Varnell ED, Thompson HW. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol 1999;127:531-6
   PubMed Web of Science ®Google Scholar
• Kaufman HE, Varnell ED, Toshida H, Effects of topical unoprostone and latanoprost on acute and re- current herpetic keratitis in the rabbit. Am J Ophthalmol 2001;131:643-6
   PubMed Web of Science ®Google Scholar
• Beam G, Reardon G, Zimmerman TJ. Association between ocular herpes simplex virus and topical ocular hypotensive therapy. J Glaucoma 2004;13:361-4
   PubMed Web of Science ®Google Scholar
• Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci 2004;81:574-7
   PubMed Web of Science ®Google Scholar
• Lee JW, Kim DY, Lee YK. Two cases of deepening of the upper lid sulcus from topical bimatoprost therapy. J Korean Ophthalmol Soc 2007;48:332-6
   Google Scholar
• Filippopoulos T, Paula JS, Torun N, Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg 2008;24:302-7
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Perren B, Iliev ME, Orbital fat atrophy in glaucoma patients treated with topical bimatoprost— can bimatoprost cause enophthalmos? Klin Monbl Augenheilkd 2008;225:443-5
   PubMed Web of Science ®Google Scholar
• Yam JC, Yuen NS, Chan CW. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther 2009;25:471-2
   PubMed Web of Science ®Google Scholar
• Yang HK, Park KH, Kim TW, Kim DM. Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol 2009;53:176-9
   PubMed Web of Science ®Google Scholar
• Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol 2011;55(1):22-7
   PubMed Web of Science ®Google Scholar
• Aihara M, Shirato S, Sakata R. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Jpn J Ophthalmol 2011;55(6):600-4
   PubMed Web of Science ®Google Scholar
• Nakakura S, Tabuchi H, Kiuchi Y. Latanoprost therapy after sunken eyes caused by travoprost or bimatoprost. Optom Vis Sci 2011;88(9):1140-4
   PubMed Web of Science ®Google Scholar
• Sudesh S, Cohen EJ, Rapuano CJ, Wilson RP. Corneal toxicity associated with latanoprost. Arch Ophthalmol 1999;117(4):539-40
   PubMedGoogle Scholar
• Morales J, Shihab ZM, Brown SM, Hodges MR. Herpes simplex virus dermatitis in patients using latanoprost. Am J Ophthalmol 2001;132(1):114-16
   PubMed Web of Science ®Google Scholar
• Kozobolis VP, Detorakis ET, Maskaleris G, Corneal sensitivity changes following the instillation of latanoprost, bimatoprost, and travoprost eyedrops. Am J Ophthalmol 2005;139(4):742-3
   PubMed Web of Science ®Google Scholar
• Szerenyi K, Sorken K, Garbus JJ, Decrease in normal human corneal sensitivity with topical diclofenac sodium. Am J Ophthalmol 1994;118:312-15
   PubMed Web of Science ®Google Scholar
• Mietz H, Niesen U, Krieglstein GK. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol 1994;232:561-5
   PubMed Web of Science ®Google Scholar
• Xu KP, Yagi Y, Tsubota K. Decrease in corneal sensitivity and change in tear function in dry eye. Cornea 1996;15:235-9
   PubMed Web of Science ®Google Scholar
• Fraunfelder FT. Extraocular fluid dynamics: how best to apply topical ocular medication. Trans Am Ophthalmol Soc 1976;74:457-87
   PubMedGoogle Scholar
• Passo MS, Palmer EA, Van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology 1984;91:1361-3
   PubMed Web of Science ®Google Scholar
• Hedner J, Everts B, Moller CS. Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation. Arch Ophthalmol 1999;117(10):1305-9
   PubMedGoogle Scholar
• Xalatan: latanoprost ophthalmic solution [package insert]. New York: Pfizer and Upjohn Co.; 2009. Available from: http://www.pfizer.com/files/products/uspi_xalatan_multi.pdf
   Google Scholar
• Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 2002;47(Suppl):S6-12
   PubMedGoogle Scholar
• Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet 2002;41:959-98
   PubMed Web of Science ®Google Scholar
• Anderson GD, Lynn AM. Optimizing pediatric dosing: a developmental pharmacologic approach. Pharmacotherapy 2009;29:680-90
   PubMed Web of Science ®Google Scholar
• Raber S, Courtney R, Maeda-Chubachi T, A6111139 Study Group. Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, Open-Label Study. Ophthalmology 2011;118(10):2022-7
   PubMed Web of Science ®Google Scholar
• Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 2000;84(7):710-13
   PubMed Web of Science ®Google Scholar
• Bull SARAC. Respiratory tract reactions to latanoprost. Swed Adverse Drug React Advisory Committee 1998;67:4-5
   Google Scholar
• Mitra M, Chang B, James T. Exacerbation of angina associated with latanoprost. BMJ 2001;323(7316):783
   PubMedGoogle Scholar
• No authors listed Cardiovascular disorder due to latanoprost eye drops? Prescr Int 1999;8(41):85
   Google Scholar
• Peak AS, Sutton BM. Systemic adverse effects associated with topically applied latanoprost. Ann Pharmacother 1998;32(4):504-5
   PubMed Web of Science ®Google Scholar
• Weston BC. Migraine headache associated with latanoprost. Arch Ophthalmol 2001;119(2):300-1
   PubMedGoogle Scholar
• Tsai JC, McClure CA, Ramos SE, Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003;12:393-8
   PubMed Web of Science ®Google Scholar